All In Biotech

Drug Trial Radar · NCT04456816

A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria

An Exploratory, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AP1189 Versus Placebo Administered for 12 Weeks as an add-on to Patients, in ACE Inhibitor or Angiotensin II Receptor Blocker Treatment, With Idiopathic Membranous Nephropathy and Severe Proteinuria

Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

23

Planned (sponsor's estimate)

Start

Aug 31, 2020

Primary completion

Jun 30, 2026

Study completion Jun 30, 2026

Sponsor

Lead sponsor
SynAct Pharma ApsIndustry
Sponsor type
Industry
First posted
Jul 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an exploratory, randomized, double-blind, multicenter, placebo-controlled study with repeated doses of AP1189. The study population will consist of patients with idiopathic membranous nephropathy (iMN) and severe proteinuria who are on ACE inhibitor or angiotensin II receptor blocker treatment.

Conditions

  • Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
  • Severe Proteinuria Due to Idiopathic Membranous Nephropathy

Interventions

  • 100 mg AP1189Drug

    100 mg AP1189 tablet

  • PlaceboDrug

    Matching placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventTime frame: Week 12
  2. Serious Adverse EventsTime frame: Week 12
  3. ALAT change in plasma samplesTime frame: Week 12
  4. ASAT change in plasma samplesTime frame: Week 12
  5. Total bilirubin change in plasma samplesTime frame: Week 12
  6. Alkaline phosphatase change in plasma samplesTime frame: Week 12
  7. Protein change in 24 hours urinary protein excretionTime frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aarhus Universitetshospital

    Aarhus, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.